Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes
Maha K. Rahim, Trine Line Hauge Okholm, Kyle B. Jones, et al.
Cell (2023) Vol. 186, Iss. 6, pp. 1127-1143.e18
Open Access | Times Cited: 218

Showing 1-25 of 218 citing articles:

Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Qian Sun, Zhenya Hong, Cong Zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 245
CD8+ T cells in the cancer-immunity cycle
Josephine R. Giles, Anna-Maria Globig, Susan M. Kaech, et al.
Immunity (2023) Vol. 56, Iss. 10, pp. 2231-2253
Open Access | Times Cited: 161
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial
Joe Y. Chang, Steven H. Lin, Wenli Dong, et al.
The Lancet (2023) Vol. 402, Iss. 10405, pp. 871-881
Open Access | Times Cited: 122
Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer
Dingjiacheng Jia, Qiwen Wang, Yadong Qi, et al.
Cell (2024) Vol. 187, Iss. 7, pp. 1651-1665.e21
Closed Access | Times Cited: 105
Stem-like exhausted and memory CD8+ T cells in cancer
Thomas Gebhardt, Simone L. Park, Ian A. Parish
Nature reviews. Cancer (2023) Vol. 23, Iss. 11, pp. 780-798
Closed Access | Times Cited: 73
T Cell Exhaustion
Andrew Baessler, Dario A.A. Vignali
Annual Review of Immunology (2024) Vol. 42, Iss. 1, pp. 179-206
Closed Access | Times Cited: 70
Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions
Haoran Ji, Chuang Hu, Xuhui Yang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 69
Principles and therapeutic applications of adaptive immunity
Hongbo Chi, Marion Pepper, Paul G. Thomas
Cell (2024) Vol. 187, Iss. 9, pp. 2052-2078
Open Access | Times Cited: 64
Localization, tissue biology and T cell state — implications for cancer immunotherapy
Jason M. Schenkel, Kristen E. Pauken
Nature reviews. Immunology (2023) Vol. 23, Iss. 12, pp. 807-823
Open Access | Times Cited: 62
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 5, pp. 572-587
Closed Access | Times Cited: 61
Enhancing head and neck tumor management with artificial intelligence: Integration and perspectives
Nian‐Nian Zhong, Hanqi Wang, Xinyue Huang, et al.
Seminars in Cancer Biology (2023) Vol. 95, pp. 52-74
Closed Access | Times Cited: 43
CD4+ T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy
Amelie Franken, Michel Bila, Aurelie Mechels, et al.
Immunity (2024) Vol. 57, Iss. 3, pp. 541-558.e7
Open Access | Times Cited: 33
Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer
Yuqing Chen, Dongfang Wang, Yingjie Li, et al.
Cancer Cell (2024) Vol. 42, Iss. 7, pp. 1268-1285.e7
Open Access | Times Cited: 23
T cell dysfunction and therapeutic intervention in cancer
Caitlin C. Zebley, Dietmar Zehn, Stephen Gottschalk, et al.
Nature Immunology (2024) Vol. 25, Iss. 8, pp. 1344-1354
Closed Access | Times Cited: 23
Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC
Yixin Zhou, Anlin Li, Hui Yu, et al.
JAMA Network Open (2024) Vol. 7, Iss. 3, pp. e241285-e241285
Open Access | Times Cited: 20
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
Fan Guan, Ruixuan Wang, Zhenjie Yi, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 3
Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer
Xinyi Guo, Hu Nie, Wenwen Zhang, et al.
Cancer Cell (2025)
Closed Access | Times Cited: 2
Impact of lymphadenectomy extent on immunotherapy efficacy in postresectional recurred non-small cell lung cancer: a multi-institutional retrospective cohort study
Hongsheng Deng, Juan Zhou, Hualin Chen, et al.
International Journal of Surgery (2023)
Open Access | Times Cited: 32
Cellular and molecular waypoints along the path of T cell exhaustion
Xin Lan, Caitlin C. Zebley, Ben Youngblood
Science Immunology (2023) Vol. 8, Iss. 87
Open Access | Times Cited: 29
Strategies to reinvigorate exhausted CD8+ T cells in tumor microenvironment
Qianting Guan, Meiwen Han, Qinghao Guo, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 24
Seizing the fate of lymph nodes in immunotherapy: To preserve or not?
Zhenyu Xu, Zi‐Zhan Li, Lei‐Ming Cao, et al.
Cancer Letters (2024) Vol. 588, pp. 216740-216740
Closed Access | Times Cited: 13
Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates
Jürgen C. Becker, Andreas Stang, David Schrama, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 4, pp. 541-557
Open Access | Times Cited: 13
Merkel cell polyomavirus-specific and CD39+CLA+ CD8 T cells as blood-based predictive biomarkers for PD-1 blockade in Merkel cell carcinoma
Heeju Ryu, Timothy Bi, Thomas H. Pulliam, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 2, pp. 101390-101390
Open Access | Times Cited: 11
Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials
Changsong Qi, Panpan Zhang, Chang Liu, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 21, pp. 2565-2577
Closed Access | Times Cited: 10
T cell exhaustion and senescence for ovarian cancer immunotherapy
Jiao Zhao, Zhongmiao Wang, Yingying Tian, et al.
Seminars in Cancer Biology (2024) Vol. 104-105, pp. 1-15
Closed Access | Times Cited: 10
Page 1 - Next Page

Scroll to top